339 related articles for article (PubMed ID: 26706476)
1. PSMA-specific theranostic nanoplex for combination of TRAIL gene and 5-FC prodrug therapy of prostate cancer.
Chen Z; Penet MF; Krishnamachary B; Banerjee SR; Pomper MG; Bhujwalla ZM
Biomaterials; 2016 Feb; 80():57-67. PubMed ID: 26706476
[TBL] [Abstract][Full Text] [Related]
2. PSMA-targeted theranostic nanoplex for prostate cancer therapy.
Chen Z; Penet MF; Nimmagadda S; Li C; Banerjee SR; Winnard PT; Artemov D; Glunde K; Pomper MG; Bhujwalla ZM
ACS Nano; 2012 Sep; 6(9):7752-7762. PubMed ID: 22866897
[TBL] [Abstract][Full Text] [Related]
3. Nanoplex delivery of siRNA and prodrug enzyme for multimodality image-guided molecular pathway targeted cancer therapy.
Li C; Penet MF; Wildes F; Takagi T; Chen Z; Winnard PT; Artemov D; Bhujwalla ZM
ACS Nano; 2010 Nov; 4(11):6707-16. PubMed ID: 20958072
[TBL] [Abstract][Full Text] [Related]
4. Delayed Progression of Lung Metastases Following Delivery of a Prodrug-activating Enzyme.
Dore-Savard L; Chen Z; Winnard PT; Krishnamachary B; Raman V; Black ME; Bhujwalla ZM
Anticancer Res; 2017 May; 37(5):2195-2200. PubMed ID: 28476782
[TBL] [Abstract][Full Text] [Related]
5. Image-guided enzyme/prodrug cancer therapy.
Li C; Penet MF; Winnard P; Artemov D; Bhujwalla ZM
Clin Cancer Res; 2008 Jan; 14(2):515-22. PubMed ID: 18223227
[TBL] [Abstract][Full Text] [Related]
6. Prostate-specific suicide gene therapy using the prostate-specific membrane antigen promoter and enhancer.
O'Keefe DS; Uchida A; Bacich DJ; Watt FB; Martorana A; Molloy PL; Heston WD
Prostate; 2000 Oct; 45(2):149-57. PubMed ID: 11027414
[TBL] [Abstract][Full Text] [Related]
7. Superiority of yeast over bacterial cytosine deaminase for enzyme/prodrug gene therapy in colon cancer xenografts.
Kievit E; Bershad E; Ng E; Sethna P; Dev I; Lawrence TS; Rehemtulla A
Cancer Res; 1999 Apr; 59(7):1417-21. PubMed ID: 10197605
[TBL] [Abstract][Full Text] [Related]
8. Yeast cytosine deaminase improves radiosensitization and bystander effect by 5-fluorocytosine of human colorectal cancer xenografts.
Kievit E; Nyati MK; Ng E; Stegman LD; Parsels J; Ross BD; Rehemtulla A; Lawrence TS
Cancer Res; 2000 Dec; 60(23):6649-55. PubMed ID: 11118048
[TBL] [Abstract][Full Text] [Related]
9. Recombinant adenovirus mediated prostate-specific enzyme pro-drug gene therapy regulated by prostate-specific membrane antigen (PSMA) enhancer/promoter.
Zeng H; Wei Q; Huang R; Chen N; Dong Q; Yang Y; Zhou Q
J Androl; 2007; 28(6):827-35. PubMed ID: 17522418
[TBL] [Abstract][Full Text] [Related]
10. Mutation of Escherichia coli cytosine deaminase significantly enhances molecular chemotherapy of human glioma.
Kaliberov SA; Market JM; Gillespie GY; Krendelchtchikova V; Della Manna D; Sellers JC; Kaliberova LN; Black ME; Buchsbaum DJ
Gene Ther; 2007 Jul; 14(14):1111-9. PubMed ID: 17495948
[TBL] [Abstract][Full Text] [Related]
11. Therapeutic efficacy of intravenously administered transferrin-conjugated dendriplexes on prostate carcinomas.
Al Robaian M; Chiam KY; Blatchford DR; Dufès C
Nanomedicine (Lond); 2014 Apr; 9(4):421-34. PubMed ID: 24910874
[TBL] [Abstract][Full Text] [Related]
12. Cytosine deaminase-producing human mesenchymal stem cells mediate an antitumor effect in a mouse xenograft model.
You MH; Kim WJ; Shim W; Lee SR; Lee G; Choi S; Kim DY; Kim YM; Kim H; Han SU
J Gastroenterol Hepatol; 2009 Aug; 24(8):1393-400. PubMed ID: 19486256
[TBL] [Abstract][Full Text] [Related]
13. Improved effects of a double suicide gene system on prostate cancer cells by targeted regulation of prostate-specific membrane antigen promoter and enhancer.
Zhang P; Zeng H; Wei Q; Lu Y; Li X; Wang J; Zhao F; Li H
Int J Urol; 2008 May; 15(5):442-8. PubMed ID: 18452463
[TBL] [Abstract][Full Text] [Related]
14. Enzyme/prodrug therapy for head and neck cancer using a catalytically superior cytosine deaminase.
Hamstra DA; Rice DJ; Fahmy S; Ross BD; Rehemtulla A
Hum Gene Ther; 1999 Aug; 10(12):1993-2003. PubMed ID: 10466633
[TBL] [Abstract][Full Text] [Related]
15. Cytosine deaminase-expressing human neural stem cells inhibit tumor growth in prostate cancer-bearing mice.
Lee HJ; Doo SW; Kim DH; Cha YJ; Kim JH; Song YS; Kim SU
Cancer Lett; 2013 Jul; 335(1):58-65. PubMed ID: 23391716
[TBL] [Abstract][Full Text] [Related]
16. Combination of cytosine deaminase with uracil phosphoribosyl transferase leads to local and distant bystander effects against RM1 prostate cancer in mice.
Khatri A; Zhang B; Doherty E; Chapman J; Ow K; Pwint H; Martiniello-Wilks R; Russell PJ
J Gene Med; 2006 Sep; 8(9):1086-96. PubMed ID: 16832832
[TBL] [Abstract][Full Text] [Related]
17. Theranostic Small-Molecule Prodrug Conjugates for Targeted Delivery and Controlled Release of Toll-like Receptor 7 Agonists.
Debnath S; Hao G; Guan B; Thapa P; Hao J; Hammers H; Sun X
Int J Mol Sci; 2022 Jun; 23(13):. PubMed ID: 35806163
[TBL] [Abstract][Full Text] [Related]
18. Exogenous cytosine deaminase gene expression in Bifidobacterium breve I-53-8w for tumor-targeting enzyme/prodrug therapy.
Hidaka A; Hamaji Y; Sasaki T; Taniguchi S; Fujimori M
Biosci Biotechnol Biochem; 2007 Dec; 71(12):2921-6. PubMed ID: 18159091
[TBL] [Abstract][Full Text] [Related]
19. A ROS-responsive polymeric prodrug nanosystem with self-amplified drug release for PSMA (-) prostate cancer specific therapy.
Wang Y; Zhang Y; Ru Z; Song W; Chen L; Ma H; Sun L
J Nanobiotechnology; 2019 Aug; 17(1):91. PubMed ID: 31451114
[TBL] [Abstract][Full Text] [Related]
20. Dihydropyrimidine Dehydrogenase Is a Prognostic Marker for Mesenchymal Stem Cell-Mediated Cytosine Deaminase Gene and 5-Fluorocytosine Prodrug Therapy for the Treatment of Recurrent Gliomas.
Chung T; Na J; Kim YI; Chang DY; Kim YI; Kim H; Moon HE; Kang KW; Lee DS; Chung JK; Kim SS; Suh-Kim H; Paek SH; Youn H
Theranostics; 2016; 6(10):1477-90. PubMed ID: 27446484
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
